<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589263</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-023-11F</org_study_id>
    <secondary_id>115,132</secondary_id>
    <secondary_id>H-27457</secondary_id>
    <nct_id>NCT01589263</nct_id>
    <nct_alias>NCT01567293</nct_alias>
  </id_info>
  <brief_title>Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS</brief_title>
  <official_title>Effectiveness of OnabotulinumtoxinA (onaBoNT-A) vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia &amp; Lower Urinary Track Symptoms (#02-10-10-05)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benign prostatic hyperplasia (BPH) and its related symptoms are a common condition that&#xD;
      affects nearly half of men over age 50 and 90% of men over 80. Lower urinary tract symptoms&#xD;
      (LUTS) caused by BPH can be very troublesome, affect an individual's quality of life&#xD;
      significantly, and are costly.&#xD;
&#xD;
      his Phase 2 clinical research trial is a double-blind, randomized, placebo-controlled,&#xD;
      parallel-group study to compare the treatment effects of onaBoNT-A 200 U versus 0.4 mg per&#xD;
      day of oral tamsulosin in male Veterans diagnosed with moderate to severe LUTS [American&#xD;
      Urologic Association Symptom Score (AUASS) equal to or greater than 8] associated with BPH. A&#xD;
      total of 74 volunteers will be recruited to participate in this clinical trial. Volunteers&#xD;
      will include only males who are greater than 50 years of age and diagnosed with LUTS&#xD;
      associated with BPH. They are Veterans who visit the Michael E. DeBakey Veterans Affairs&#xD;
      Medical Center - Houston (MEDVAMC). There are no eligibility restrictions as to race or&#xD;
      ethnicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposed intervention is the first randomized clinical trial comparing the effects of&#xD;
      onaBoNT-A prostate injection versus alpha adrenergic antagonist medication for LUTS&#xD;
      associated with BPH. Up to this point, clinical studies using onaBoNT-A in the prostate has&#xD;
      been limited to patient's refractory to -1 adrenoceptor blocker therapy. The study will&#xD;
      directly compare onaBoNT-A against -1 adrenoceptor blockers as frontline therapy in a male&#xD;
      Veteran cohort suffering from moderate to severe LUTS. Besides its obvious efficacy in&#xD;
      patients' refractory to -1 adrenoceptor blocker therapy, onaBoNTA injection has several&#xD;
      potential advantages over oral agents. Focal prostate injection has been shown to be safe and&#xD;
      obviates the systemic side effects observed with -1 adrenoceptor blockers (i.e. orthostatic&#xD;
      hypotension, sexual dysfunction). In addition, most clinical studies demonstrate a durable&#xD;
      response to onaBoNT-A treatment exceeding 12 months. Although this study is of modest length&#xD;
      (i.e. total 4 years), significant results could drive paradigm shifts in how LUTS associated&#xD;
      with BPH is treated, even with regards to frontline therapy.&#xD;
&#xD;
      Although sophisticated molecular techniques (i.e. LCM with Microarray Analysis) have been&#xD;
      used by other investigators to characterize gene profile changes with BPH and LUTS, this will&#xD;
      be the first study examining gene profile changes in drug na ve BPH View Protocol Record&#xD;
      patients following treatment with the -1 adrenoceptor blocker Tamsulosin or onaBoNT-A. This&#xD;
      study is important because scant knowledge exists on the true mechanisms by which -1&#xD;
      adrenoceptor blockers like Tamsulosin or onaBoNT-A improve patient urinary tract symptoms and&#xD;
      quality of life. It is clear, however, that nerves not only regulate prostate growth and&#xD;
      function but also account for LUTS that drive patients to seek therapy. This investigation&#xD;
      will utilize onaBoNT-A as a biological tool to identify potential novel mechanistic pathways&#xD;
      for future investigation that will push the development of targeted therapy to benefit those&#xD;
      patients refractory to all pharmacologic treatment. Potential inflammatory pathways or neural&#xD;
      sensory signaling alterations induced by BPH, which are modified by onaBoNT-A or Tamsulosin&#xD;
      to improve symptoms via gene profile changes, can be explored by expert laboratories in the&#xD;
      Texas Medical Center. This is a highly collaborative project utilizing expertise across&#xD;
      departments that will foster translational work from the laboratory to the patient. Although&#xD;
      not the primary goal of this study, the investigators will also search for possible&#xD;
      biological markers with prognostic value that could be confirmed in a future multi-center&#xD;
      trial.&#xD;
&#xD;
      The primary objective of this Phase 2 clinical research study is to compare the efficacy of&#xD;
      200 U onaBoNT-A injected into the prostate versus oral tamsulosin for the treatment of lower&#xD;
      urinary tract symptoms caused by BPH in male Veteran volunteers at the MEDVAMC. The secondary&#xD;
      objective is to determine the impact of tamsulosin and onaBoNT-A on the pathologic parameters&#xD;
      and RNA profiles of epithelium and stroma in BPH tissues.&#xD;
&#xD;
      Volunteers will be randomized into two groups with one receiving ona-BoNT-A injection into&#xD;
      the prostate and an oral placebo pill taken once daily and the other group will receive a&#xD;
      placebo injection and an oral tamsulosin pill once daily.&#xD;
&#xD;
      Volunteers will make five clinic visits and be contacted by telephone twice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2012</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American Urologic Association Symptom Score (AUASS)</measure>
    <time_frame>3 months</time_frame>
    <description>AUA Symptom Score on a scale of 0 to 35, 35 is the worse outcome and 0 is the best outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Track Symptoms</condition>
  <arm_group>
    <arm_group_label>ARM 1: onaBoNT-A + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>onaBoNT-A 200 U prostate injection and placebo oral capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2: Saline + Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onaBoNT-A + placebo</intervention_name>
    <description>200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo</description>
    <arm_group_label>ARM 1: onaBoNT-A + placebo</arm_group_label>
    <arm_group_label>ARM 2: Saline + Tamsulosin</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin + placebo</intervention_name>
    <description>0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
    <arm_group_label>ARM 1: onaBoNT-A + placebo</arm_group_label>
    <arm_group_label>ARM 2: Saline + Tamsulosin</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males at least 50 years of age&#xD;
&#xD;
          -  American Urological Association Symptom Score greater than 8&#xD;
&#xD;
          -  Voided volume greater than 125 ml&#xD;
&#xD;
          -  Maximum urinary flowrate less than 15 ml/sec.&#xD;
&#xD;
          -  Must agree to all procedures and willfully consented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior surgical intervention or use of 5-alpha-reductase medical intervention for&#xD;
             BPH&#xD;
&#xD;
          -  Current diagnosis of acute or chronic prostatitis (which may cause LUTS that mimic&#xD;
             BPH)&#xD;
&#xD;
          -  Previous exposure to onabotulinumtoxinA&#xD;
&#xD;
          -  Overactive bladder without obstructive symptoms (i.e. decrease in force of stream,&#xD;
             hesitancy, intermittency, post-void dribbling)&#xD;
&#xD;
          -  Active urinary tract disease or biopsy of the prostate within the past 6 weeks;&#xD;
&#xD;
          -  Two documented urinary tract infections of any type in the past year (UTI defined as&#xD;
             greater than 100,000 colonies per ml urine from midstream clean catch or catheterized&#xD;
             specimen)&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  History of bladder calculi (stones)&#xD;
&#xD;
          -  Penile prosthesis or artificial urinary sphincter [placement]&#xD;
&#xD;
          -  Documented bacterial or acute prostatitis within the past year&#xD;
&#xD;
          -  Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack,&#xD;
             or cerebrovascular accident (stroke) within the past 6 months&#xD;
&#xD;
          -  Known primary neurologic conditions such as multiple sclerosis, myasthenia gravis or&#xD;
             Parkinson's disease, or other neurological diseases known to affect bladder function&#xD;
&#xD;
          -  History or current evidence of carcinoma of the prostate or bladder, pelvic radiation&#xD;
             or surgery, urethral stricture, or bladder neck obstruction&#xD;
&#xD;
          -  Cancer that is not considered cured, except basal cell or squamous cell carcinoma of&#xD;
             the skin (cured defined as no evidence of cancer within the past 5 years)&#xD;
&#xD;
          -  Any serious medical condition that is likely to impede successful completion of the&#xD;
             study, such as certain mental disorders, hypersensitivity to onabotulinumtoxinA or&#xD;
             anesthetics used in the study, syncope&#xD;
&#xD;
          -  Daily use of a pad or device for incontinence required&#xD;
&#xD;
          -  Interested in future fertility&#xD;
&#xD;
          -  Postvoid Residual (PVR) greater than 350 ml&#xD;
&#xD;
          -  Serum prostate specific antigen (PSA) level greater than 8 ng/ml (Hybritech). For&#xD;
             those with a PSA between 4-8 ng/ml, the PSA elevation must be considered to be from a&#xD;
             benign cause in the opinion of the PI. This decision can be based on PSA velocity,&#xD;
             previous TRUS (transrectal ultrasound) biopsy, percent free PSA, or other clinical&#xD;
             estimations in keeping with sound urologic care&#xD;
&#xD;
          -  Has taken phenylephrine, pseudoephedrine, imipramine, an anticholinergic, or&#xD;
             cholinergic medication within the past 2 weeks&#xD;
&#xD;
          -  Has taken estrogen, androgen, any drug producing androgen suppression, or anabolic&#xD;
             steroids within the past 4 months&#xD;
&#xD;
          -  Taking aminoglycosides or any drug that interfere with neuromuscular transmission.&#xD;
             Eaton-Lambert syndrome, hemophilia, hereditary clotting factors deficiency, or&#xD;
             bleeding diathesis&#xD;
&#xD;
          -  Must be off aspirin, NSAIDS, and Coumadin for 7 or more days prior to&#xD;
             onabotulinumtoxinA injection&#xD;
&#xD;
          -  Enrolled in another treatment trial for any disease within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males at least 50 years of age</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher P Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michael E. DeBakey VA Medical Center, Houston, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Mynderse LA, Roehrborn CG, Smith CP, Bruskewitz R. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011 Sep;186(3):965-70. doi: 10.1016/j.juro.2011.04.062. Epub 2011 Jul 24.</citation>
    <PMID>21791356</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004 Jun;171(6 Pt 1):2128-37. Review.</citation>
    <PMID>15126771</PMID>
  </results_reference>
  <results_reference>
    <citation>Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, Aoki KR. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol. 2008 Jun;5(6):319-28. doi: 10.1038/ncpuro1124. Epub 2008 May 6. Review.</citation>
    <PMID>18461049</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <results_first_submitted>September 8, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Lower Urinary Track Symptoms</keyword>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01589263/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01589263/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>63 subjects were consented and Informed Consent was signed by all of the subjects. These subjects were selected from PI's medical clinic. PI and the CRC explained the study to these subjects but only 21 participants started the intervention.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ARM 1: onaBoNT-A + Placebo</title>
          <description>onaBoNT-A 200 U prostate injection and placebo oral capsule daily&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
        <group group_id="P2">
          <title>ARM 2: Saline + Tamsulosin</title>
          <description>Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARM 1: onaBoNT-A + Placebo</title>
          <description>onaBoNT-A 200 U prostate injection and placebo oral capsule daily&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
        <group group_id="B2">
          <title>ARM 2: Saline + Tamsulosin</title>
          <description>Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.35" spread="1.35"/>
                    <measurement group_id="B2" value="1.725" spread="1.725"/>
                    <measurement group_id="B3" value="1.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Volume</title>
          <description>Normal Range : 20-30 ccs</description>
          <units>CC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.79" spread="26.79"/>
                    <measurement group_id="B2" value="32.33" spread="32.33"/>
                    <measurement group_id="B3" value="29.56" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUA Symptom Score</title>
          <description>AUA Score Index 0 - 7 Mild 8-19 Moderate 20-35 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.92" spread="22.92"/>
                    <measurement group_id="B2" value="22.78" spread="22.78"/>
                    <measurement group_id="B3" value="22.85" spread="22.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BPH Impact Score</title>
          <description>BPH Impact Score&#xD;
Minimum: 0 (No urinary condition) Maximum: 13 (Higher number indicates the urinary condition)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.83" spread="7.83"/>
                    <measurement group_id="B2" value="6.11" spread="6.11"/>
                    <measurement group_id="B3" value="6.97" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bladder Function Score</title>
          <description>Sum of the RDMS Questionnaire results are graded for bladder function:&#xD;
Minimum Score: 0 indicates that there is no issue with the bladder function. Maximum Score: 24 indicates the severity of the issue with the bladder function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.58" spread="7.58"/>
                    <measurement group_id="B2" value="7.44" spread="7.44"/>
                    <measurement group_id="B3" value="7.51" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erectile Function Score</title>
          <description>22-25: No erectile dysfunction, 17-21: Mild erectile dysfunction ,12-16: Mild to moderate erectile dysfunction ,8-11: Moderate erectile dysfunction, 5-7: Severe erectile dysfunction.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.58" spread="21.58"/>
                    <measurement group_id="B2" value="29.56" spread="29.56"/>
                    <measurement group_id="B3" value="25.57" spread="25.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejaculation Function Score</title>
          <description>On the scale of 0-35 on ejaculation score index:&#xD;
Score of 0: Is a good ejaculation score. Score of 35: Is graded as a disease severity on ejaculation score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.58" spread="20.58"/>
                    <measurement group_id="B2" value="17.44" spread="17.44"/>
                    <measurement group_id="B3" value="19.01" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American Urologic Association Symptom Score (AUASS)</title>
        <description>AUA Symptom Score on a scale of 0 to 35, 35 is the worse outcome and 0 is the best outcome.</description>
        <time_frame>3 months</time_frame>
        <population>Volunteers were randomized on a 1:1 assignment by the MEDVAMC Research Pharmacy to either: ARM 1: BoNT-A 200 U prostate injection and placebo oral capsule daily or ARM 2: Placebo prostate injection (saline) and Tamsulosin 0.4 mg capsule daily.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 1: onaBoNT-A + Placebo</title>
            <description>onaBoNT-A 200 U prostate injection and placebo oral capsule daily&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
          </group>
          <group group_id="O2">
            <title>ARM 2: Saline + Tamsulosin</title>
            <description>Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
          </group>
        </group_list>
        <measure>
          <title>American Urologic Association Symptom Score (AUASS)</title>
          <description>AUA Symptom Score on a scale of 0 to 35, 35 is the worse outcome and 0 is the best outcome.</description>
          <population>Volunteers were randomized on a 1:1 assignment by the MEDVAMC Research Pharmacy to either: ARM 1: BoNT-A 200 U prostate injection and placebo oral capsule daily or ARM 2: Placebo prostate injection (saline) and Tamsulosin 0.4 mg capsule daily.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.66" spread="0.07"/>
                    <measurement group_id="O2" value="14.16" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19.6 month period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARM 1: onaBoNT-A + Placebo</title>
          <description>onaBoNT-A 200 U prostate injection and placebo oral capsule daily&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
        <group group_id="E2">
          <title>ARM 2: Saline + Tamsulosin</title>
          <description>Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.&#xD;
onaBoNT-A + placebo: 200 U prostate injection once&#xD;
Arms: ARM 1: onaBoNT-A + placebo&#xD;
Tamsulosin + placebo: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Unrelated</sub_title>
                <description>One patient was removed due to serious adverse event unrelated to participation in the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Unrelated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Smith</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-4001</phone>
      <email>cps@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

